Lincoln Pharmaceuticals declares 18% dividend; Q4 FY26 results announced
Lincoln Pharmaceuticals reported Q4 FY26 results with total income of ₹183.08 crore and net profit of ₹116.35 crore. For the full year FY26, total income was ₹704.48 crore and net profit was ₹878.94 crore. The company recommended an 18% dividend (₹1.80 per share) for FY26, pending AGM approval.
The announcement includes the company's financial performance for the quarter and year, along with a dividend recommendation. This information is material for investors and can impact stock valuation.
The company reported positive financial results with an increase in revenue and profit, and recommended a dividend, which is generally viewed positively by investors.
Lincoln Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026, following a Board of Directors meeting held on May 28, 2026. The company reported total income of ₹183.08 crore for the quarter and ₹704.48 crore for the year ended March 31, 2026. Net profit for the quarter stood at ₹116.35 crore, while the full year net profit was ₹878.94 crore. The company's Board has recommended a dividend of 18%, amounting to ₹1.80 per equity share of face value ₹10, for the financial year ended March 31, 2026. This dividend is subject to the approval of the members at the upcoming Annual General Meeting (AGM). The financial results, including both standalone and consolidated statements, received unmodified audit reports from the statutory auditors. The audited financial results will also be available on the company's website, www.lincolnpharma.com.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.